Subject: RE: Submission to ICDC-DGAB-CanGlioma01

Date: Tuesday, January 7, 2020 at 10:12:20 Eastern Standard Time

From: Khan, Javed (NIH/NCI) [E]

To: Warren A Kibbe, Ph.D., Leblanc, Amy (NIH/NCI) [E], Sommers, Connie (NIH/NCI) [E]

CC: Beyers, Matthew (NIH/NCI) [C], William Hendricks, Matthew Breen, Kim, Erika (NIH/NCI) [E], Dearry, Allen (NIH/NCI) [E], Roel Verhaak, Tawa, Gregory (NIH/NCATS) [E]

I agree with Connie and approve submission and the Jax group and the ICDC can work on modifications as needed.

From: Khan, Javed (NIH/NCI) [E]
Sent: Tuesday, January 7, 2020 8:07 AM
To: Warren A Kibbe, Ph.D. <warren.kibbe@duke.edu>; Leblanc, Amy (NIH/NCI) [E] <amy.leblanc@nih.gov>; Sommers, Connie (NIH/NCI) [E] <SommersC@mail.nih.gov>
Cc: Beyers, Matthew (NIH/NCI) [C] <matthew.beyers@nih.gov>; William Hendricks <whendricks@tgen.org>; Matthew Breen <mbreen3@ncsu.edu>; Kim, Erika (NIH/NCI) [E] <erika.kim@nih.gov>; Dearry, Allen (NIH/NCI) [E] <allen.dearry@nih.gov>; Roel Verhaak <Roel.Verhaak@jax.org>; Tawa, Gregory (NIH/NCATS) [E] <gregory.tawa@nih.gov>
Subject: RE: Submission to ICDC-DGAB-CanGlioma01

Dear Warren,

Thanks for forwarding this exciting new study which will be valuable data for mining by the research community.

Since this is the first time that I am doing this, I have some questions on the files you sent:

1. In the Table S1 Case metadata, I don't see a subject ID, or Case ID but do see a sample barcode. How will investigators who want to use this data know which tumor is coming from which dog in cases where there are multiple tumors from one dog, or which normal is paired with which tumor in a given patient?
2. Assuming each row is a sample (which may be an incorrect assumption) I did not see any normal tissue data which would be important for data analysis.
3. Some of the abbreviations are not explained, and because I am not a dog genomics expert it is not easy to work out what they mean. For example the TSS column what does CSU, AU, TAMU, UCD, etc. mean. Similarly the CBTC defined histopathological classification are difficult to interpret without subject knowledge or a key.

Amy and Connie do we approve via email, or do we need to have a conference call to discuss?

Javed

From: Warren A Kibbe, Ph.D. <warren.kibbe@duke.edu>
Sent: Monday, January 6, 2020 10:51 PM
To: Leblanc, Amy (NIH/NCI) [E] <amy.leblanc@nih.gov>; Sommers, Connie (NIH/NCI) [E] <sommersc@mail.nih.gov>; Khan, Javed (NIH/NCI) [E] <khanjav@mail.nih.gov>
Cc: Beyers, Matthew (NIH/NCI) [C] <matthew.beyers@nih.gov>; William Hendricks <whendricks@tgen.org>; Matthew Breen <mbreen3@ncsu.edu>; Kim, Erika (NIH/NCI) [E] <erika.kim@nih.gov>; Dearry, Allen (NIH/NCI) [E] <allen.dearry@nih.gov>; Roel Verhaak <Roel.Verhaak@jax.org>; Tawa, Gregory (NIH/NCATS) [E]

<gregory.tawa@nih.gov>
Subject: FW: Submission to ICDC-DGAB-CanGlioma01

Dear Drs. Kahn, LeBlanc, and Sommers,

We, the ICDC Data Governance Advisory Board, have received our first data submission form, a very exciting event! We met and discussed the submission today, and we are very pleased to recommend that the submission to be approved by the NIH ICDC Senior Advisory Committee and are therefore forwarding the submission request to you for your review. In addition to the attached submission materials, the ICDC help desk has identified a few things that will need to be curated before the final deposit into the ICDC, as spelled out in the email below.

Please let me or Matt Beyers know if you need any more information or clarification.

My best,

Warren

From: ICDC Help Desk <ICDCHelpDesk@mail.nih.gov>
Date: Monday, January 6, 2020 at 15:50
To: Roel Verhaak <Roel.Verhaak@jax.org>, Samir Amin <Samir.Amin@jax.org>
Cc: "Leblanc, Amy (NIH/NCI) [E]" <amy.leblanc@nih.gov>, "Otridge, John (NIH/NCI) [C]" <john.otridge@nih.gov>, "Musk, Philip (NIH/NCI) [C]" <philip.musk@nih.gov>, "Beyers, Matthew (NIH/NCI) [C]" <matthew.beyers@nih.gov>, Warren A Kibbe <warren.kibbe@duke.edu>, "Wolfe, Claire (NIH/NCI) [C]" <wolfec@mail.nih.gov>, "Hecht, Toby (NIH/NCI) [E]" <hechtt@mail.nih.gov>
Subject: Re: Submission to ICDC-DGAB-CanGlioma01

Hi Roel and Samir,

Thank you for your recent submission to the Integrated Canine Data Commons (ICDC). The Data Governance Advisory Board reviewed your submission today and has agreed to prioritize its entry into ICDC. As discussed on the call today, we have identified this as study "CanGlioma01" – please let us know if you would like a different designation.

As part of that discussion, we visually identified several fields of data where standardization is needed. Standardization of values is critical for findability and reusability of the data by the users and is the responsibility of the submitter, in cooperation with the ICDC. The ICDC Data Team will work with the submitter to provide guidance on which standard terms/values should be used (e.g., breeds as defined in the NCI Thesaurus), how those changes can be made before the submitter makes the changes prior to final submission. The ICDC Data Team should not make these changes because we are not the data subject matter experts and, while this places an additional burden on the submitter, the ICDC data team will work closely with the submitter to identify areas needing to be standardized and to suggest those standard terms/values. Our Data Team can also suggest tools and methodologies for making any changes. We expect there to be a close relationship during the data curation process. The ICDC is currently in the prototype phase and during this phase there are funds available to help with the expense of curating the data into the state/format ready for ICDC acceptance. We can also discuss how those funds can be made available should you need them.

Philip Musk, our data team lead, will be in contact with Samir to start the process of identifying and suggesting changes. This may require changes to the data model on our end as well and so everyone should be aware that this is an iterative process, especially as the ICDC is still in prototype phase.

Eventually, we hope to provide a submitter validation tool that can be utilized prior to submission – issues identified during this iterative process will help us develop that tool.

We thank you in advance for your patience and efforts and for your willingness to share data with the ICDC.

Best regards,

Matt

_____
Matthew Beyers, MSc, PMP (contractor)
Technical Project Manager
Frederick National Laboratory for Cancer Research
Leidos Biomedical Research, Inc.
9605 Medical Center Drive, Room 300-10
Rockville, MD 20874
Tel: (240) 276-6616
Matthew.beyers@nih.gov

From: "Beyers, Matthew (NIH/NCI) [C]" <beyersm@nih.gov> on behalf of ICDC Help Desk <ICDCHelpDesk@mail.nih.gov>
Date: Thursday, January 2, 2020 at 10:25
To: Roel Verhaak <Roel.Verhaak@jax.org>
Cc: Samir Amin <Samir.Amin@jax.org>
Subject: Re: Submission to ICDC-DGAB

Happy New Year Greetings,

We acknowledge receipt of your proposal and will advise further once the Data Governance Advisory Board has reviewed it.

Best regards,

Matt

From: Roel Verhaak <Roel.Verhaak@jax.org>
Date: Tuesday, December 31, 2019 at 11:43
To: ICDC Help Desk <ICDCHelpDesk@mail.nih.gov>
Cc: Samir Amin <Samir.Amin@jax.org>
Subject: Submission to ICDC-DGAB

We would like to submit our canine glioma sequencing datasets to ICDC-DGAB. Following the guidelines provided by Ralph Parchment and Matt Beyers, we prepared the attached documents. Please review and let us know if anything needs to be revised.

Kind regards and happy new year,

Samir Amin & Roel Verhaak

Roel Verhaak, PhD
Professor and Associate Director of Computational Biology
Jackson Laboratory for Genomic Medicine
Ten Discovery Drive
Farmington, CT 06032

Phone: 860-837-2105
E-mail: roel.verhaak@jax.org
Web: https://www.jax.org/research-and-faculty/research-labs/the-verhaak-lab
Twitter: https://twitter.com/#!/roelverhaak

The Jackson Laboratory
Bar Harbor, ME **|** Farmington, CT **|** Sacramento, CA
www.jax.org